Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension.

[1]  Shujing Jane Lim,et al.  Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta‐aggregation , 2021, The journal of pathology. Clinical research.

[2]  H. Gevensleben,et al.  Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial , 2020, The Lancet. Oncology.

[3]  Xiaoxuan Liu,et al.  Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension , 2020, Nature medicine.

[4]  C. Swanton,et al.  The National Lung Matrix Trial of personalized therapy in lung cancer , 2020, Nature.

[5]  E. Provenzano,et al.  The important role of the histopathologist in clinical trials: challenges and approaches to tackle them , 2020, Histopathology.

[6]  R. Kravitz,et al.  SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist , 2020, BMJ.

[7]  C. Moskaluk,et al.  Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. , 2019, American journal of clinical pathology.

[8]  Jens Rittscher,et al.  The use of digital pathology and image analysis in clinical trials , 2019, The journal of pathology. Clinical research.

[9]  Karin Oien,et al.  Training and accreditation standards for pathologists undertaking clinical trial work , 2019, The journal of pathology. Clinical research.

[10]  Karin Oien,et al.  Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work , 2018, The journal of pathology. Clinical research.

[11]  Joanna Coast,et al.  Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension , 2018, JAMA.

[12]  K. O’Brien,et al.  Development of a core outcome set for orthodontic trials using a mixed-methods approach: protocol for a multicentre study , 2017, Trials.

[13]  Timothy J. Wood,et al.  Using consensus group methods such as Delphi and Nominal Group in medical education research* , 2017, Medical teacher.

[14]  Emilio Bria,et al.  Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. , 2016, Breast.

[15]  L. Esserman,et al.  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group , 2015, Modern Pathology.

[16]  C. Röcken.  Quality assurance in clinical trials—the role of pathology , 2015, Virchows Archiv.

[17]  Harlan M Krumholz,et al.  Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.

[18]  R. Tibshirani,et al.  Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.

[19]  I. Nagtegaal,et al.  Pathology is a necessary and informative tool in oncology clinical trials , 2014, The Journal of pathology.

[20]  Anil V Parwani,et al.  Central pathology review for phase III clinical trials: the enabling effect of virtual microscopy. , 2013, Archives of pathology & laboratory medicine.

[21]  D. Rennie,et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.

[22]  David Moher,et al.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.

[23]  Joshua LaBaer,et al.  Improving international research with clinical specimens: 5 achievable objectives. , 2012, Journal of proteome research.

[24]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[25]  Jacqueline A. Hall,et al.  Integrating collection of biospecimens in clinical trials: the approach of the European organization for research and treatment of cancer. , 2011, Biopreservation and biobanking.

[26]  R. Schilsky,et al.  Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Lawrence D. True,et al.  Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents , 2010, Clinical Cancer Research.

[28]  Anna Kelsey,et al.  Central pathology review in multicenter trials and studies , 2009, Cancer.

[29]  Marcella Sarzotti-Kelsoe,et al.  Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials , 2009, PLoS medicine.

[30]  D. Altman,et al.  Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation , 2007, Trials.

[31]  D. Ruiter,et al.  The role of the EORTC pathologist in clinical trials: achievements and perspectives. European Organisation for Research and Treatment of Cancer. , 2002, European journal of cancer.

[32]  I. Olkin,et al.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.